Consolidated Portfolio Review Corp »

Alnylam Pharmaceuticals shares owned by Consolidated Portfolio Review Corp

Quarter-by-quarter ownership of Alnylam Pharmaceuticals (ALNY) shares owned by Consolidated Portfolio Review Corp from 13F filings

Historical chart of Consolidated Portfolio Review Corp investment in Alnylam Pharmaceuticals

Tip: Access up to 7 years of quarterly data

All positions including Alnylam Pharmaceuticals held by Consolidated Portfolio Review Corp consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Alnylam Pharmaceuticals by Consolidated Portfolio Review Corp

Quarter filed Position value Share count Share price at filing
2025-09-30 $274k 601 456.00

More positions owned by Consolidated Portfolio Review Corp

Apple (AAPL)
Microsoft Corporation (MSFT)
Vanguard Bd Index Fds Intermed Term (BIV)
Vanguard Index Fds Growth Etf (VUG)
Ishares Tr Rus 1000 Grw Etf (IWF)
Vanguard Index Fds Value Etf (VTV)
Fidelity Wise Origin Bitcoin SHS (FBTC)
Strategy Cl A New (MSTR)
Vanguard Tax-managed Fds Van Ftse Dev Mkt (VEA)
Invesco Exchange Traded Fd T S&p 500 Top 50 (XLG)
NVIDIA Corporation (NVDA)
Goldman Sachs Etf Tr Activebeta Us Lg (GSLC)
Amazon (AMZN)
Vanguard World Health Car Etf (VHT)
Schwab Strategic Tr Us Lrg Cap Etf (SCHX)

View all positions for Consolidated Portfolio Review Corp

Top funds holding Alnylam Pharmaceuticals

FMR
Capital World Investors
Vanguard Group
BlackRock
Capital Research Global Investors
Jpmorgan Chase & Co
Groupama Asset Managment
State Street Corporation
Baillie Gifford & Co
Geode Capital Management
Dodge & Cox
T. Rowe Price Investment Management
Orbis Allan Gray
Wellington Management Company
Susquehanna International

View all funds holding Alnylam Pharmaceuticals